Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial".

Freeman WD, Kuo R, Aguilar MI.

Stroke. 2012 Jul;43(7):e63. doi: 10.1161/STROKEAHA.112.660407. No abstract available.

3.

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, Ezekowitz MD, Yusuf S.

Stroke. 2012 Jun;43(6):1511-7. doi: 10.1161/STROKEAHA.112.650614.

4.
5.
7.
8.

Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis".

Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.

Circulation. 2014 Nov 25;130(22):e195. doi: 10.1161/CIRCULATIONAHA.114.012350. No abstract available.

9.

Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.

Eikelboom JW, Hart RG.

Stroke. 2015 Jan;46(1):5-6. doi: 10.1161/STROKEAHA.114.007486. No abstract available.

12.

Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.

Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse HF, Siu CW.

Stroke. 2015 Jan;46(1):23-30. doi: 10.1161/STROKEAHA.114.006476.

13.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289.

PMID:
21041570
14.

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.

Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747.

15.
17.

Letter by Hifumi et al regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".

Hifumi T, Takada H, Kiriu N.

Circulation. 2014 Sep 2;130(10):e94. doi: 10.1161/CIRCULATIONAHA.113.008378. No abstract available.

18.

Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K.

Stroke. 2014 Aug;45(8):2286-91. doi: 10.1161/STROKEAHA.114.006016.

19.

Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.

Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators..

Eur J Heart Fail. 2013 Sep;15(9):1053-61. doi: 10.1093/eurjhf/hft111.

20.

Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.

Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators..

Circ J. 2011;75(4):800-5.

Supplemental Content

Support Center